Q1 2024 · 13F-HR
venBio Partners LLCholdings as filed
Filed 2024-05-15 · accession 0000905148-24-001442
$281.9M
Reported value
5
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $108.2M | 38.4% | 9,699,925 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $99.1M | 35.2% | 4,289,304 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $34.8M | 12.3% | 1,035,396 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $26.0M | 9.23% | 3,852,470 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $13.8M | 4.91% | 2,696,133 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.